ArticleMedical physics2016
Stratification of pseudoprogression and true progression of glioblastoma multiform based on longitudinal diffusion tensor imaging without segmentation.
Article in Medical physics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Artificial intelligence algorithms for differentiating pseudoprogression from true progression in high-grade gliomas: A systematic review and meta-analysis.Neurosurgical review · 2025Pooled it
- Machine learning imaging applications in the differentiation of true tumour progression from treatment-related effects in brain tumours: A systematic review and meta-analysis.Journal of medical imaging and radiation oncology · 2022Pooled it
- Timepoint-Specific Benchmarking of Deep Learning Models for Glioblastoma Follow-Up MRI.Cancers · 2025Article
- Decoding Glioblastoma Heterogeneity: Neuroimaging Meets Machine Learning.Neurosurgery · 2025Review
- Improved brain tumor diagnostics and follow-up with novel magnetic resonance imaging methods: A single center study protocol.PloS one · 2025Article
- The University of California San Francisco Adult Longitudinal Post-Treatment Diffuse Glioma MRI Dataset.Radiology. Artificial intelligence · 2024Article
- Article
- Imaging Role in Diagnosis, Prognosis, and Treatment Response Prediction Associated with High-grade Glioma.Journal of medical signals and sensors · 2024Review
- Radiomics analysis of amide proton transfer-weighted and structural MR images for treatment response assessment in malignant gliomas.NMR in biomedicine · 2023Article
- A Survey of Radiomics in Precision Diagnosis and Treatment of Adult Gliomas.Journal of clinical medicine · 2022Review
- High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 1: Perfusion and Diffusion Techniques.Frontiers in oncology · 2022Review
- Differentiation of Pseudoprogression from True Progressionin Glioblastoma Patients after Standard Treatment: A Machine Learning Strategy Combinedwith Radiomics Features from TBMC medical imaging · 2021Article
- Radiomics and Deep Learning from Research to Clinical Workflow: Neuro-Oncologic Imaging.Korean journal of radiology · 2020Review
- Machine learning and glioma imaging biomarkers.Clinical radiology · 2020Review
- Optimizing Neuro-Oncology Imaging: A Review of Deep Learning Approaches for Glioma Imaging.Cancers · 2019Review
- Review
- Machine learning studies on major brain diseases: 5-year trends of 2014-2018.Japanese journal of radiology · 2019Review
- Prediction of Pseudoprogression versus Progression using Machine Learning Algorithm in Glioblastoma.Scientific reports · 2018Article
- MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives.Journal of immunology research · 2017Review
- CombinedNeuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposePseudoprogression (PsP) can mimic true tumor progression (TTP) on magnetic resonance imaging in patients with glioblastoma multiform (GBM). The phenotypical similarity between PsP and TTP makes it a challenging task for physicians to distinguish these entities. So far, no approved biomarkers or computer-aided diagnosis systems have been used clinically for this purpose.
methodsTo address this challenge, the authors developed an objective classification system for PsP and TTP based on longitudinal diffusion tensor imaging. A novel spatio-temporal discriminative dictionary learning scheme was proposed to differentiate PsP and TTP, thereby avoiding segmentation of the region of interest. The authors constructed a novel discriminative sparse matrix with the classification-oriented dictionary learning approach by excluding the shared features of two categories, so that the pooled features captured the subtle difference between PsP and TTP. The most discriminating features were then identified from the pooled features by their feature scoring system. Finally, the authors stratified patients with GBM into PsP and TTP by a support vector machine approach. Tenfold cross-validation (CV) and the area under the receiver operating characteristic (AUC) were used to assess the robustness of the developed system.
resultsThe average accuracy and AUC values after ten rounds of tenfold CV were 0.867 and 0.92, respectively. The authors also assessed the effects of different methods and factors (such as data types, pooling techniques, and dimensionality reduction approaches) on the performance of their classification system which obtained the best performance.
conclusionsThe proposed objective classification system without segmentation achieved a desirable and reliable performance in differentiating PsP from TTP. Thus, the developed approach is expected to advance the clinical research and diagnosis of PsP and TTP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.